Project Grant R43CA298194
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...
- This $399,300 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an innovative cancer immunotherapy approach at Tiba Biotech LLC, a biotechnology company based in Cambridge, Massachusetts. Specifically, the grant funds the creation of a targeted delivery system that combines enhanced self-amplifying RNA (esRNA) technology and spleen-targeting nanoparticle delivery materials. This platform is designed to stimulate a...
- This $406,500 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel intratumoral delivery system by Absco Therapeutics, Inc. (Abscotx) to enhance solid tumor immunotherapy. The Oncolymer platform utilizes a thermoresponsive hydrogel and FDA-approved imaging agent to enable sustained, localized delivery of therapeutic agents like immune-sensitizing siRNA and the TLR7 agonist imiquimod. Preclinical studies have...
- The National Cancer Institute (NCI) awarded Shasqi Inc., a biotechnology company based in San Francisco, a $1,094,189 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports Shasqi's development of its Click Activated Protodrugs (CAPAC) platform, which aims to improve the therapeutic efficacy of cancer treatments by facilitating precise and localized activation of potent cytotoxic drugs. This approach seeks to minimize systemic toxicity and...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded Nightstar Biotechnologies, Inc. a $360,442 Project Grant to develop an artificial intelligence (AI) platform called PMTNET for designing optimal therapeutic T-cell receptor (TCR-T) cells to treat cholangiocarcinoma (CCA). The PMTNET platform aims to address the challenges in traditional TCR-T cell design by predicting TCR-antigen interactions to enable targeting of minimally expressed tumor antigens while avoiding...
- The National Cancer Institute (NCI) awarded Gigamune, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentiviral vector for enhanced in vivo delivery of T cell receptors for cell therapy to treat Stage IV melanoma. The project aims to address challenges with current autologous T cell therapies, such as high costs and limited manufacturing capacity, by engineering innovative gene delivery methods to potentially increase patient access...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- The National Cancer Institute (NCI) awarded a $306,871 Project Grant to Vivere Oncotherapies, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to advance the development of their OV-151 oncolytic virotherapy product for the treatment of colorectal cancer. The project aims to: 1) characterize the delivery properties of the OV-151 clinical vector to tumors, 2) optimize the therapeutic cargo delivered by the vector, and 3) develop an inducible promoter to enhance...